PTIE reports PTI-555 Phase II data

Pain Therapeutics (PTIE) said preliminary analysis of a double-blind, 210-patient U.S. Phase II trial of PTI-555 reached its primary endpoint of pain relief compared to morphine (p<0.01) or placebo (p...